ALS MyMatch – ACACIA: Trial of Oral Digoxin in ALS

Join us on June 9th, 11:00am ET for a webinar introducing the first Healey ALS MyMatch clinical trial- the ACACIA trial of oral digoxin. 

Healey ALS MyMatch is a novel, patient-centered, early phase, clinical trial initiative launched by the Healey & AMG Center for ALS at MGH. ALS MyMatch is a series of unique, custom-designed, Phase 1b/2a clinical trials, built using an agile infrastructure and precision medicine approach in ALS.

This initiative represents an important step forward in identifying the right individuals for the right trials that match their disease biology. ALS MyMatch trials utilize genetic and biofluid markers (biomarkers) to select participants and assess a range of investigational products in a robust and rapid manner. The results of these early phase trials will help identify promising therapies for further evaluation in future HEALEY ALS Platform Trial regimens or standalone clinical efficacy trials.

Learn more about this groundbreaking program and hear from the ACACIA trial Principal investigators (PIs), Drs. Suma Babu and Brian Wainger, who will share key insights into the digoxin trial.